Report
A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors
Michael W. Bishopa Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA;b Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USACorrespondence[email protected]
https://orcid.org/0000-0003-3926-1446View further author information
https://orcid.org/0000-0003-3926-1446View further author information, , Jacquelyn A. Hankd Department of Human Oncology, University of Wisconsin, Madison (UW), WI, USAhttps://orcid.org/0000-0002-1402-3540View further author information
https://orcid.org/0000-0002-1402-3540View further author information, Paul M. Sondeld Department of Human Oncology, University of Wisconsin, Madison (UW), WI, USA;e Departments of Pediatrics and Genetics, University of Wisconsin, Madison (UW), WI, USAhttps://orcid.org/0000-0002-0981-8875View further author information
https://orcid.org/0000-0002-0981-8875View further author information, , , & show all